Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: A randomized and prospective study

Schwarzer, 2001, The prevalence of Peyronie’s disease, BJU Int, 88, 727, 10.1046/j.1464-4096.2001.02436.x Chiang, 1992, Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie’s disease, Eur Urol, 21, 48, 10.1159/000474800 Briganti, 2003, Peyronie’s disease, Curr Opin Urol, 13, 417, 10.1097/00042307-200309000-00010 Dang, 2004, Intralesional interferon-α 2b injections for the treatment of Peyronie’s disease, South Med J, 97, 42, 10.1097/01.SMJ.0000056658.60032.D3 Benson, 1991, Interferon-α 2b in the treatment of Peyronie’s disease, J Urol, 145, 1342A Wegner, 1997, Local interferon-α 2b is not an effective treatment in early-stage Peyronie’s disease, Eur Urol, 32, 190, 10.1159/000480857 Brake, 2001, Treatment of Peyronie’s disease with local interferon-α 2b, BJU Int, 87, 654, 10.1046/j.1464-410x.2001.02139.x Judge, 1997, Intralesional interferon in the treatment of Peyronie’s disease, Br J Urol, 79, 40, 10.1046/j.1464-410X.1997.02849.x Ahuja, 1999, A pilot study demonstrating clinical benefit from intralesional interferon-α 2b in the treatment of Peyronie’s disease, J Androl, 20, 444 Prieto Castro, 2003, Combined treatment with vitamin E and colchicines in the early stages of Peyronie’s disease, BJU Int, 91, 522, 10.1046/j.1464-410X.2003.04134.x Levine, 1994, Intralesional verapamil injection for the treatment of Peyronie’s disease, J Urol, 151, 1522, 10.1016/S0022-5347(17)35291-6 Devine, 1997, Proposal, J Urol, 157, 285, 10.1016/S0022-5347(01)65361-8 Hellstrom, 2000, Peyronie’s disease, J Androl, 21, 347 Moreland, 2002, Pathophysiology of Peyronie’s disease, Int J Impot Res, 14, 406, 10.1038/sj.ijir.3900875 Somers, 1997, Fibrin deposition in Peyronie’s disease plaque, J Urol, 157, 311, 10.1016/S0022-5347(01)65367-9 Pryor, 2002, Clinical presentation of Peyronie’s disease, Int J Impot Res, 14, 414, 10.1038/sj.ijir.3900877 Gholami, 2003, Peyronie’s disease, J Urol, 169, 1234, 10.1097/01.ju.0000053800.62741.fe Davis, 1997, The microscopic pathology of Peyronie’s disease, J Urol, 157, 282, 10.1016/S0022-5347(01)65360-6 Brock, 1997, The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease, J Urol, 157, 276, 10.1016/S0022-5347(01)65359-X Vahlensieck, 1995, Penile ossification and acquired penile deviation, Eur Urol, 27, 252, 10.1159/000475172 Devine, 1992, Peyronie’s disease, vol 6, 3011 Ludwig, 1991, Evaluation of conservative therapeutic approaches to Peyronie’s disease (fibrotic induration of the penis), Urol Int, 47, 236, 10.1159/000282228 Duncan, 1991, Resolution of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferon-alpha, -beta, and -gamma, Scand J Urol Nephrol, 25, 89, 10.3109/00365599109024539 Ahuja, 1998, Intralesional injection of alpha-interferon-2b in the treatment of Peyronie’s disease, J Urol, 159, 117A Scardino, 1949, The use of tocopherols in the treatment of Peyronie’s disease, Ann NY Acad Sci, 52, 390, 10.1111/j.1749-6632.1949.tb55300.x Chesney, 1975, Peyronie’s disease, Br J Urol, 47, 209, 10.1111/j.1464-410X.1975.tb03950.x Scott, 1947, New concept in the treatment of Peyronie’s disease, South Med J, 41, 173, 10.1097/00007611-194802000-00017 Pryor, 1983, Controlled clinical trial of vitamin E in Peyronie’s disease, Prog Reprod Biol Med, 9, 41 Gelbard, 1990, The natural history of Peyronie’s disease, J Urol, 144, 1376, 10.1016/S0022-5347(17)39746-X